Home > Archive > HIV Aids > November 2005 > Re: NATAP: Pfizer CCR5 Drug Notes Case of Liver Toxicity





You are viewing an archived Text-only version of the thread. To view this thread in it's original format and/or if you want to reply to this thread please [click here]

Author Re: NATAP: Pfizer CCR5 Drug Notes Case of Liver Toxicity
GMCarter

2005-11-24, 10:50 am

On 23 Nov 2005 10:25:51 -0800, "DavidT" <david199@volcanomail.com>
wrote:

>One factor against a class effect may be the fact that the molecules
>are quite different.


? I think it's not the character of the molecules, but rather a
disputation of the rather glib notion that blocking CCR5 won't have
any physiological effect because some people live without it. (Others
might suggest that such individuals have learned to compensate for the
reduced or eliminated expression).

Oh--but you could be right that this is NOT a class effect (i.e., R5
is important for some aspects of liver function) but rather the
molecular interaction with the liver or other receptors may be causing
the transaminase and bilirubin spikes.....

Time will tell....I still think the effort should be on T20-like
molecules that inhibit the binding site on HIV--but preferably small
molecules.

And more integrase, nef, tat, vpr inhibitors and the like!

George M. Carter

Copyright 2003 - 2009 pahealthsystems.com